Cardiovascular disease

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Retrieved on: 
Tuesday, April 30, 2024
Climate change, Food, Stroke, World Health Organization, Risk, Climate, Health, Infection, City, Diabetes, Research, Growth, Obesity, Disease, Poverty, Bill, Cardiovascular disease, Notifiable disease, Novo Nordisk Foundation, Tuberculosis, Knowledge, Agriculture

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.

Key Points: 
  • The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
  • The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them.
  • "At the Novo Nordisk Foundation, we work to improve the health of people and the planet," says Mads Krogsgaard Thomsen, CEO of the Foundation.
  • "These are closely connected but, all too often, scientific research occurs in silos and the outcomes don't meet the needs of a world facing complex challenges.

5 Ways Heart Health Care Can Improve

Retrieved on: 
Monday, April 29, 2024
The Harris Poll, Education, Brain, Public, Cancer, Food, Disorder, FAHA, Stroke, Pneumonia, Housing, Prevalence, CVD, Risk, Health, Infection, Heart, Radiology, Death, Research, Artificial intelligence, Life, Stanford School, Disease, Moyamoya disease, Physician, Cardiovascular disease, Diphtheria, Roflumilast, Tuberculosis, Overalls, American Heart Association, Heart failure, Pharmaceutical industry

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."

Key Points: 
  • "Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."
  • Non-traditional approaches to health care are needed to address the social and structural determinants of health by moving evidence-based approaches rapidly into communities to address food insecurity, transportation problems, education, housing, access to care, chronic psychosocial stress and other social needs.
  • The interconnectedness of organ systems, mechanisms of disease and stages of life are critical to understanding the role cardiovascular health plays in overall health.
  • As we apply these same clinical and epidemiological methods to the someday hopeful eradication of heart disease and stroke, the American Heart Association is making great progress.

Valbiotis publishes its annual accounts 2023

Retrieved on: 
Friday, May 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
Thursday, April 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Retrieved on: 
Wednesday, April 24, 2024
American Heart, FDA, Patient, HealthyWomen, University, Stroke, Professional corporation, Risk, Woman, Food, CVD, Health, Death, Fenofibrate, History, Prescription, Science, CFR, Commissioner, Cardiovascular disease, Clinical trial, Associate, Amarin, Medical director, Pharmaceutical industry

“Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.

Key Points: 
  • “Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.
  • This results in patients taking a drug proven to have no clinical benefit to reduce CVD risk,” said Nabil Abadir, M.D., Chief Medical Officer at Amarin.
  • “This is a significant issue that is risking patient health and should be addressed quickly by the FDA.
  • The petition also urges the FDA Commissioner to further clarify the position the agency previously took by removing the statin co-administration from fenofibrate labeling.

Accounting for the Role of Gender is Critical to Maximizing Philanthropic Impact, According to Study

Retrieved on: 
Wednesday, April 24, 2024
Cancer, Learning, Social change, Risk, Woman, Research, The Bridgespan Group, Black, Culture, Gender, Face, Cardiovascular disease, Toy

Debby Bielak, a co-author and Bridgespan partner says, “The fact is, many funders don’t consider gender equity when they think about impact, and even when they do, they approach gender only as its own discrete program area.

Key Points: 
  • Debby Bielak, a co-author and Bridgespan partner says, “The fact is, many funders don’t consider gender equity when they think about impact, and even when they do, they approach gender only as its own discrete program area.
  • Design a portfolio that addresses gender in your issue area: Whom and what might you fund differently?
  • Consider funding more women-led organizations and collaboratives that focus on gender equity, including feminist funds.
  • Evolve your organization to support your gender aspirations: Revisit your organization’s culture, grantmaking processes, measurement, and structure to ensure they align with your gender equity goals.

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Retrieved on: 
Wednesday, April 24, 2024
Heart, Blood, European Patent Convention, Hypertrophy, ECG, HSCS, Intelligence, Environment, Patent, Patient, Death, Cardiovascular disease, Growth, Medical device

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.

Key Points: 
  • Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.
  • Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy.
  • Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging.
  • The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences, with patent expiration dates ranging from March 2031 through August 2040.

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Retrieved on: 
Monday, April 22, 2024
FDA, Weill Cornell Medicine, Patient, Fast Track, Phenotype, Death, Cardiomyopathy, Research, Natural history, IND, Cornell University, Senior, Friedreich's ataxia, Cardiovascular disease, Therapy, Orphan drug, Pharmaceutical industry

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

Key Points: 
  • Under the license agreement, Lexeo has acquired certain rights1 including rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy ( NCT05302271 ).
  • The agreement will support Lexeo’s efforts to develop a potentially life-changing therapy for this unmet need.
  • Lexeo previously licensed know-how relating to AAVrh.10hFXN from Weill Cornell Medicine and collaborated with researchers there to further study the candidate, which Lexeo refers to as LX2006.
  • “This agreement with Lexeo Therapeutics builds upon years of collaboration between Weill Cornell Medicine and Lexeo to benefit patients with FA cardiomyopathy.

VIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth

Retrieved on: 
Monday, April 22, 2024
Mortality, FDA, Patient, Pharmacy, Risk, Food, Hunger, Weight loss, Partnership, Obesity, Exercise, Dyslipidemia, Type 2 diabetes, Hypertension, Cardiovascular disease, Phentermine, Prevalence, Ageing

CAMPBELL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced it has entered into a strategic partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company. The program, titled “VIVUS Engage,” will establish a robust online telemedicine platform for the distribution of QSYMIA® (phentermine and topiramate extended-release capsules CIV), the leading non-injectable branded weight loss medication in the U.S. for adults.

Key Points: 
  • Under the terms of the agreement, UpScript LLC will make QSYMIA available to patients through its proprietary Telehealth Platform.
  • With over 20 years of experience and more than one million patients served, UpScriptHealth specializes in creating effective web-based campaigns for pharmaceutical companies.
  • For patients actively seeking online support and solutions, UpScriptHealth offers a fast and convenient option.
  • Combined with a healthy diet and exercise, it has been proven to help patients lose weight and maintain weight loss.

Solera Health Expands its Curated Network to Help Payers and Employers Address High-Cost Cardiometabolic Disease

Retrieved on: 
Tuesday, April 16, 2024
Mortality, Genetics, International Journal of Obesity, Diabetes, Weight loss, Obesity, Solera, Patient, Movement, Hypertension, Cardiovascular disease, Longevity, Anxiety, Sleep, HALO, Disease, Pharmaceutical industry

The additional solutions enable payers and employers to address high-cost conditions associated with cardiometabolic health – integrating several proven, industry-leading digital health partners.

Key Points: 
  • The additional solutions enable payers and employers to address high-cost conditions associated with cardiometabolic health – integrating several proven, industry-leading digital health partners.
  • New solutions enhance Solera’s ability to impact hypertension, high cholesterol, diabetes prevention and weight management – and include Ciba Health, Digbi Health and Wondr Health.
  • Diabetes and cardiovascular disease are among the most expensive and prevalent diseases in the U.S., affecting over 121 million Americans.
  • "Cardiometabolic conditions remain a leading cause of preventable morbidity and mortality while accounting for over 30% of healthcare costs in the United States alone,” said Dr. Byron Crowe, Chief Medical Officer at Solera Health.